Semaglutide

Active ingredient description

Semaglutide is a GLP-1 receptor agonist. It acts in the same way as GLP-1 (a hormone produced in the gut) by increasing the amount of insulin that the pancreas releases in response to food. This helps with the control of blood glucose levels.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
A10BJ06
A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10B Blood glucose lowering drugs, excl. insulins → A10BJ Glucagon-like peptide-1 (GLP-1) analogues
Discover more medicines within A10BJ06

Medicines

Semaglutide is the active ingredient of these drugs:

Drug
Countries
OZEMPIC

Australia Austria Brazil Canada Cyprus

RYBELSUS

Brazil Canada Estonia Finland Ireland

WEGOVY

Canada Estonia Lithuania Poland United States

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
OZEMPIC Solution for injection
Summary of Product Characteristics (SPC)
RYBELSUS Tablet
Structured Product Labeling (SPL/PLR)
US

Structural formula

Graphic representation of the active ingredient's molecular structure

Molecular mass: 4113.641 g/mol

External identifiers

CAS Substance: 910463-68-2
DrugBank Drug: DB13928
RxNorm Ingredient: 1991302
SNOMED-CT Concept: 764283003
Semaglutide (substance)
UNII Identifier: 53AXN4NNHX
SEMAGLUTIDE
 
Next: Usage >